# COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research

> **NCT06168032** · NA · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 1224 (estimated)

## Conditions studied

- COVID-19 Recurrent
- Lung Cancer
- Vaccination
- Antibody
- Chemotherapy
- Immune Checkpoint Inhibitor

## Interventions

- **BIOLOGICAL:** Any Chinese government-recommended COVID-19 booster vaccine

## Key facts

- **NCT ID:** NCT06168032
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-08
- **Primary completion:** 2026-12-08
- **Final completion:** 2026-12-08
- **Target enrollment:** 1224 (ESTIMATED)
- **Last updated:** 2023-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06168032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06168032, "COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06168032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*